PATENT CLAIM ANALYSIS

Application Number: 16240673
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-07
Patent Classification: ["514", "178000"]

Abstract:
Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Claim (Index 4):
The method of  claim 3 , wherein the neurodegenerative disease is selected from Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD), Huntington's Disease, prion disease, motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, neuronal loss, cognitive defect, primary age-related tauopathy (PART)/Neurofibrillary tangle-predominant senile dementia, chronic traumatic encephalopathy including dementia pugilistica, dementia with Lewy bodies, neuroaxonal dystrophies, and multiple system atrophy, progressive supranuclear palsy, Pick's Disease, corticobasal degeneration, some forms of frontotemporal lobar degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17, Lytico-Bodig disease (Parkinson-dementia complex of Guam), ganglioglioma, gangliocytoma, meningioangiomatosis, postencephalitic parkinsonism, subacute sclerosing panencephalitis, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease, and lipofuscinosis.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 99.0
- Lexical Diversity: 1.06667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15666503', '12312543', '14978964', '15323552', '14336634']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7630137233060006
- 35 USC 102 Novelty (BERT): 0.4922840140084248
- Combined Prediction Score: 0.735940752376243
- Mean Citation Score: 195.090478
- Max Citation Score: 208.21414
- Similarity Product: 147.32034878641485

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test